Premium
The effects of PGF 2 α, PGI 2 , and TXB 2 on human CFU‐C in healthy and leukemic patients
Author(s) -
Gross Samuel,
WorthingtonWhite Diana A.
Publication year - 1984
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830160403
Subject(s) - alpha (finance) , chemotherapy , bone marrow , medicine , leukemia , endocrinology , biology , zoology , surgery , construct validity , patient satisfaction
This study was undertaken to test the effects of certain arachidonate derivatives, PGF 2 α, PGI 2 and TxB 2 on in vitro bone marrow granulocyte colony growth (CFU‐C) in leukemia patients receiving maintenance chemotherapy and in normal controls. The addition of PGF 2 α did not result in increased numbers of colonies, but it did cause a shift in the size of the colonies so that there was a significant increase in larger colonies (P < 0.001) and significantly fewer small colonies (P < 0.05) as compared to untreated samples. Of the prostenoids tested in a Tris‐buffered system, PGI 2 affected the greatest increase in CFU‐C (P < 0.01) followed by PGF 2 α (P < 0.05) whereas 6‐keto‐PGF 1 α (the stable hydrate of PGI 2 ) did not affect colony growth. Time‐response curves revealed a linear growth pattern for PGF 2 α with a peak at 10 days, whereas there was a 6‐day growth lag with PGI 2 followed by linear growth with a peak at 13 days. TxB 2 added to cultures significantly reduced the number of bone marrow CFU‐C at all doses tested. The prostanoid effects on CFU‐C derived from leukemic patients on maintenance chemotherapy and from normal individuals were identical in every respect.